• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Management of ocular inflammation and pain using novel insert

Article

ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).

Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019 American Society of Cataract and Refractive Surgery meeting: "Management of Ocular Inflammation and Pain Following Cataract Surgery with Dexamethasone 0.4 mg Insert (Dextenza, Ocular Therapeutix)."

Related Videos
© 2024 MJH Life Sciences

All rights reserved.